

~ Updates on HPMS Memos ~

CMS Memo Title & Release Date	Reminder About Rental Support and General Supports for Living as Special Supplemental Benefits for Chronically Ill Enrollees – Dated 08/27/2021
Summary	The Centers for Medicare & Medicaid Services (CMS) reminds Medicare Advantage (MA) plans that they are able to provide rental support and other general supports for living as a special supplemental benefit for chronically ill enrollees under certain conditions.
Action	Refer to memo for complete details.
CMS Memo Title & Release Date	Long-Term Institutionalized Resident Report – Dated 08/27/2021
Summary	The third 2021 LTI Resident Report will be distributed to plans on August 31 st , 2021. Organizations will only receive an LTI report if they have LTI enrollees. The layout of the file is provided.
Action	Applicable to PACE.
CMS Email Title & Release Date	Coverage Gap Discount Program: September Participating Labeler Codes – Dated 08/30/2021
Summary	CMS will make the following updates to the list of participating manufacturer labeler codes by September 1, 2021. Added: 74528 – Rhythm Pharmaceuticals, Inc. 82066 – GC Mogam, Inc.
Action	Although the Coverage Gap Discount Program does not apply to PACE, the participating labeler codes are applicable because only brand name prescriptions with NDCs from these codes are accepted for Part D payment. Pharmastar has made the necessary software adjustments to accommodate for the updated codes.
CMS Memo Title & Release Date	Correction to Contract Year 2022 Part D Medication Therapy Management Program Guidance and Submission Instructions dated April 30, 2021 – Dated 08/31/2021
Summary	CMS releases this memo to issue a correction to the April 30, 2021 HPMS memo entitled “Contract Year 2022 Part D Medication Therapy Management Program Guidance and Submission Instructions”. The correction pertains to the Targeted Beneficiaries section that references the 2021 MTM program annual cost threshold, which is \$4,376, not \$4,396.

Action	Applicable to plans who have a formal MTM program and utilize a formulary.
CMS Memo Title & Release Date	Information for the Second Contract Year (CY) 2022 Drug Pricing and Plan Benefit Previews – Dated 09/01/2021
Summary	This memo provides a summary of known and resolved issues as well as some general reminders in preparation for the second MPF plan preview, which is scheduled for Tuesday, September 7, 2021 at 6:00 a.m. ET through Friday, September 10, 2021 at 11:59 p.m. ET. Refer to memo for a list of known issues as well as outstanding issues.
Action	Informational to PACE as PACE plans do not have drug pricing data on Plan Finder but should ensure their organization data is displayed accurately.
CMS Memo Title & Release Date	Contract Year 2022 Translated Model Materials Requirements and Language Data Analysis Methodology – Dated 09/01/2021
Summary	CMS reminds plans that they must translate materials into any non-English language that is the primary language of at least 5 percent of the individuals in a plan benefit package (PBP) service area. CMS has prepared a file to assist. Instructions to locate the data and a path to the HPMS Material Language Lookup module are provided.
Action	Applicable to PACE. Refer to memo for complete details.
CMS Memo Title & Release Date	Release of Contract Year 2022 Plan Correction Module – Dated 09/02/2021
Summary	CMS announced the release of the HPMS Plan Correction Module, which allows sponsors to submit plan corrections for CY 2022 Medicare advantage and PBP's from September 3rd – 23rd. Navigation path is provided within the memo.
Action	Refer to memo for complete details if this may be applicable to your plan.
CMS Memo Title & Release Date	Designation of Identity Management (IDM) Plan User Approver/External Point of Contact (EPOC) – ACTION – Dated 09/02/2021
Summary	This letter describes the requirements and process that contracts must use to designate staff that will be responsible for granting access to data in the CMS systems, as well as the responsibilities of a MAO/PDP CMS External Point of Contact.
Action	Applicable to PACE. Refer to memo for complete details.
CMS Memo Title & Release Date	Re-Determination of Part D Low-Income Subsidy Eligibility for 2022 – Dated 09/02/2021
Summary	CMS released a memorandum to provide plan sponsors with information and guidance regarding how people qualify for LIS. Part D sponsors should encourage individuals to apply for LIS and assist with the process.

Action	Applicable to PACE. Refer to memo for complete details.
CMS Email Title & Release Date	Contract Year 2022 (CY) Online Enrollment Center (OEC) Opt-In Process – Dated 09/03/2021
Summary	CMS reminds that regardless of CY 2021 OEC participation status, all SNP, 1876 Cost, and RFB plans will be placed in an “opt-out” status when the CY 2022 OEC opt-in window opens on September 13, 2021. To participate in OEC for CY 2022, these plans must opt-in via HPMS once again. Changes to the opt-in or opt-out status for a given plan will be reflected on Medicare Plan Finder within approximately 24 hours.
Action	Informational to PACE.
CMS Memo Title & Release Date	2020 Attestations of Prescription Drug Event (PDE) Data, Direct and Indirect Remuneration (DIR) Data, Monthly Plan-to-Plan (P2P) Reconciliation Payments, and the Detailed DIR Report – Dated 09/03/2021
Summary	<p>CMS requires all plans that were active in 2020 to electronically sign and attest to the below Part D data in HPMS:</p> <ul style="list-style-type: none"> -2020 Data Relating to CMS Payment to Medicare Part D Sponsor -2020 Data Relating to Detailed DIR Report (except for PACE plans that submitted zero total dollars on their 2020 DIR Summary Report) -2020 Record and Attestation of P2P Reconciliation Payments <p>Completion of the Record of P2P Reconciliation Payments must be uploaded to HPMS at the same time the Plan to Plan Reconciliation Payment Data is signed. The attestations will be available through HPMS on September 3rd, 2021 to September 10th, 2021 Noon ET and is to be signed by the CEO, CFO, or COO.</p>
Action	Applicable to PACE. Refer to the memo for complete details on how to complete the attestations. Pharmastar can assist and is available to answer any questions you may have on the Record of P2P Reconciliation Payments. If Pharmastar generated the Detailed DIR data for your plan, an attestation will be provided for your records to certify that the information provided is accurate, complete and truthful based on Pharmastar best knowledge, information, and belief.
CMS Memo Title & Release Date	Second Plan Preview of 2022 Star Ratings Data – Dated 09/07/2021
Summary	CMS provided information to Part C and Part D Sponsors to preview their Star Ratings Data in HPMS prior to display on the Medicare Plan Finder. The preview window will be available September 8th – September 15th, 2020. Instructions are included in the memo.

Action	Informational to PACE.
CMS Email Title & Release Date	New Contact Field in the SPAP/ADAP Module in the Health Plan Management System (HPMS) – Dated 09/09/2021
Summary	<p>Effective September 10th, 2021 CMS will be updating the HPMS SPAP/ADAP (State Pharmaceutical Assistance Program/AIDS Drug Assistance Program) module to include the two fields listed below:</p> <ul style="list-style-type: none"> • Contact Information for CMS • Contact Information for Beneficiary Inquiries <p>CMS recommends programs to review both contact fields to ensure the appropriate information is reflected for public display on Medicare.gov.</p>
Action	Refer to memo for details.
CMS Memo Title & Release Date	CMS Update on Medicare Part D Payments to Medicare-Medicaid Plans for Contract Year 2021– Dated 09/09/2021
Summary	This notice provides information to Medicare-Medicaid Plans (MMPs) regarding the CY 2021 Part D Administrative Cost Ratio for the purposes of Part D risk corridor reconciliation for programs. The CY 2021 Part D Administrative Cost Ratio for MMPs is 22%. This percentage will be used for the reconciliation of the CY 2021 Part D risk corridors applicable to MMPs for the direct subsidy portion of the Part D payment.
Action	Refer to memo for details.

For the latest CMS response to COVID-19, please visit the CMS.gov website.

Please note that this information is provided to you in summary form for general informational purposes only and does not constitute legal or regulatory compliance advice. It is your responsibility to consult with your Compliance Officer and/or legal counsel to determine applicability of any regulation or standards referenced herein to your organization and/or processes.